Abstract
A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm3 and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
Get full access to this article
View all access options for this article.